Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped No enrollment

Conditions

CTLA4 Haploinsufficency
Chronic Cytopenia

Interventions

DRUG: abatacept
OTHER: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)